Insulet Corporation PODD recently made its Omnipod 5 Automated Insulin Delivery (“AID”) System commercially available in Australia. Omnipod 5 is available with Dexcom G6 and G7 continuous glucose ...

Insulet (PODD) on Tuesday priced a private placement of $450M aggregate principal amount of senior unsecured notes due 2033, for net proceeds of about $444.4M.

Independent Advisor Alliance grew its position in Insulet Co. (NASDAQ:PODD – Free Report) by 20.8% in the 4th quarter, ...

Shares of Insulet Corp. PODD slid 5.93% to $266.68 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.37% ...

Insulet stock opened at $270.81 on Tuesday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The firm has a market cap of $19.02 billion, a P/E ...

Click here to discover the nuances of Insulet with our detailed analytical report. NasdaqGS:PODD Revenue & Expenses Breakdown as at Mar 2025 Insulet (NasdaqGS:PODD) has rewarded its shareholders ...

Insulet (PODD) reported $597.5 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 17.2%. EPS of $1.15 for the same period compares to $1.40 a year ago.

Below is Validea's guru fundamental report for INSULET CORP (PODD). Of the 22 guru strategies we follow, PODD rates highest using our Twin Momentum Investor model based on the published strategy ...

On Thursday, Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the consensus of $1.02. The automated insulin delivery ...

Insulet (PODD) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.40 per share a year ago. These figures ...